Vergent Bioscience Secures $21.5 Million Series B Financing To Advance Clinical Development Of Tumor-Targeted Fluorescent Imaging Agent Vgt-309
Amount Raised
$21.5 Million
Round Type
Series B
MinneapolisBiotechnologyHealth CareTherapeuticsDescription
Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, today announced the close of a $21.5 million Series B financing. Vergent will use the funds to advance clinical development of VGT-309, the company’s targeted fluorescent imaging agent that enables surgeons to see previously undetected or difficult-to-find tumors in real-time, ensuring all tumor tissue is removed during open, minimally invasive (MIS) and robotic-assisted surgical procedures.
Quick answer
Vergent Bioscience raised $21.5 Million in a Series B round, dated October 4, 2022. Vergent Bioscience is based in Minneapolis, Minnesota, United States.
- How much did Vergent Bioscience raise?
- Vergent Bioscience raised $21.5 Million in a Series B round on October 4, 2022.
- What does Vergent Bioscience do?
- Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.
- Where is Vergent Bioscience based and how big is it?
- Vergent Bioscience is based in Minneapolis, Minnesota, United States.
- Who are the decision-makers at Vergent Bioscience?
- Fundz holds 1 contact at Vergent Bioscience, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Vergent Bioscience that raised within 45 days of this round, from Fundz verified event records.
- Arialys Therapeutics raised $14M on November 18, 2022.
- Parabilis Medicines raised $178M on November 17, 2022.
- Cue Biopharma raised an undisclosed amount (Funding Round) on November 17, 2022.
- Cue Biopharma raised $30M on November 16, 2022.
- Phio Pharmaceuticals raised $2K (Seed) on November 16, 2022.
- Os Therapies raised $2M on November 16, 2022.
Who to call at Vergent Bioscience, and when
A new round usually means Vergent Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Vergent Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vergent Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vergent Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vergent Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansVergent Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.